Obesity is a chronic, relapsing medical condition defined by excess adiposity that impairs health. Clinically, it is commonly measured using body mass index (BMI), where BMI is calculated as weight in kilograms divided by height in meters squared. Adult obesity is generally categorized as BMI ≥ 30 kg/m², with increasing severity at higher BMI thresholds. Although BMI is useful for population risk stratification, it does not directly measure body fat distribution; therefore, clinicians also consider waist circumference, metabolic markers, and functional status to refine risk assessment.
At the physiologic level, obesity results from an imbalance between energy intake and energy expenditure, but the underlying mechanisms are complex and multifactorial. Appetite regulation involves central and peripheral pathways, including hypothalamic signaling (e.g., melanocortin system, leptin-melanocortin feedback), and vagal afferents that integrate gastrointestinal nutrient signals. Leptin, secreted by adipose tissue, modulates energy intake and thermogenesis through neuroendocrine circuits; in many people with obesity, leptin signaling is functionally impaired (“leptin resistance”), contributing to persistent hyperphagia or reduced satiety. Reward-related pathways in the mesolimbic system also influence eating behavior, linking palatable food cues to increased consumption.
Obesity is strongly associated with insulin resistance and the metabolic syndrome. Excess visceral adipose tissue releases pro-inflammatory cytokines and adipokines (such as TNF-α, IL-6, and reduced adiponectin), promoting systemic low-grade inflammation. This inflammatory milieu contributes to endothelial dysfunction, dyslipidemia, and impaired glucose homeostasis. As adipose tissue expands beyond its healthy storage capacity, ectopic lipid deposition can occur in liver, muscle, and pancreas, worsening insulin resistance and increasing risk for type 2 diabetes mellitus.
The health risks of obesity are extensive. Cardiovascular disease risk increases through mechanisms including hypertension, atherogenic dyslipidemia (elevated triglycerides, reduced HDL), chronic inflammation, and prothrombotic changes. Obesity also increases the likelihood of obstructive sleep apnea, through fat deposition around upper airway structures and reduced ventilatory drive during sleep. Other common complications include nonalcoholic fatty liver disease, gallbladder disease, osteoarthritis from increased mechanical load, and certain cancers (e.g., endometrial, postmenopausal breast, colorectal, kidney), with risk influenced by hormonal changes such as higher estrogen availability from peripheral aromatization in adipose tissue.
Clinically, effective management begins with assessment of comorbidities and risk. Routine screening includes measurement of BMI and waist circumference, blood pressure, fasting or hemoglobin A1c for glycemic status, lipid panels, liver enzymes, and evaluation for obstructive sleep apnea based on symptoms (snoring, witnessed apneas, daytime sleepiness). Clinicians should also consider psychosocial comorbidities: depression, anxiety, stigma, and disordered eating patterns may coexist and can affect adherence to treatment.
Evidence-based treatment follows a stepwise, individualized approach. Lifestyle intervention is foundational and includes a calorie deficit through dietary pattern changes, increased physical activity, and behavioral strategies such as goal setting, self-monitoring, and problem-solving. Diet quality matters: emphasis on fiber-rich foods, adequate protein, reduced intake of added sugars and refined carbohydrates, and limiting ultra-processed foods can improve satiety and cardiometabolic outcomes. Physical activity improves insulin sensitivity and cardiorespiratory fitness even when weight loss is modest; resistance training is particularly important for preserving lean mass.
Pharmacotherapy is appropriate for many patients when lifestyle changes are insufficient and BMI meets eligibility criteria (or when obesity is accompanied by significant comorbidities). Anti-obesity medications target appetite, satiety, and metabolic pathways, and typically should be used alongside ongoing lifestyle therapy. In appropriately selected patients with severe obesity or obesity with high-risk comorbidities, bariatric and metabolic surgery can achieve substantial and sustained weight loss and can improve diabetes, sleep apnea, and cardiovascular risk factors.
Because obesity is chronic, relapse prevention is essential. Long-term follow-up supports adherence, monitors nutritional adequacy (particularly after surgery), and addresses psychological barriers. Clinicians should treat weight-related comorbidities directly and emphasize function and metabolic health, not only scale weight.
Prevention strategies include maintaining a healthy diet, limiting sedentary time, encouraging physical activity across the lifespan, and addressing social determinants that shape eating environments. In public health terms, obesity is influenced by policy and access to healthy foods, safe spaces for exercise, and healthcare availability.
Finally, it is important to distinguish medical obesity from weight-based stigma. Obesity management should be compassionate and clinically grounded: weight stigma can worsen stress, discourage healthcare engagement, and reduce effectiveness of interventions. A medical approach recognizes obesity as a multifactorial disease requiring sustained, evidence-based treatment and supportive care. Source: @Next_andReady
(((Civil_DiscourseNY)))🇺🇸🇮🇱🇺🇸🇮🇷🇺🇸: It’s not because of Cenk’s fat mouth but probably because Cenk’s fat body can’t fit on a plane. #breaking
— @Next_andReady May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
